For: | Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin Cases 2019; 7(11): 1270-1281 [PMID: 31236391 DOI: 10.12998/wjcc.v7.i11.1270] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v7/i11/1270.htm |
Number | Citing Articles |
1 |
Hsu-Heng Yen, Yang-Yuan Chen, Jun-Hung Lai, Hung-Ming Chen, Chih-Ta Yao, Siou-Ping Huang, I-Ling Liu, Ya-Huei Zeng, Fang-Chi Yang, Fu-Yuan Siao, Mei-Wen Chen, Pei-Yuan Su. Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. Journal of Clinical Medicine 2022; 11(7): 1853 doi: 10.3390/jcm11071853
|
2 |
Joan Martínez-Campreciós, Mar Riveiro-Barciela, Raquel Muñoz-Gómez, María-Carlota Londoño, Mercé Roget, Miguel Ángel Serra, Desamparados Escudero-García, Laura Purchades, Manuel Rodríguez, Juan E. Losa-García, María L. Gutiérrez, Isabel Carmona, Javier García-Samaniego, Luís Morano, Ignacio Martín-Granizo, Marta Montero-Alonso, Martín Prieto, Manuel Delgado, Natalia Ramos, María A. Azancot, Francisco Rodríguez-Frías, Maria Buti. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy. Gastroenterología y Hepatología 2023; 46(8): 594 doi: 10.1016/j.gastrohep.2022.12.004
|
3 |
Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit, Ezequiel Ridruejo. Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología (English Edition) 2021; 41(5): 578 doi: 10.1016/j.nefroe.2021.11.011
|
4 |
Patricio E. Ray, Asha Moudgil, Aditi Sinha. Pediatric Nephrology. 2022; : 707 doi: 10.1007/978-3-030-52719-8_101
|
5 |
Chien‐Hsueh Tung, Chung‐Yi Li, Yen‐Chun Chen, Yi‐Chun Chen. Association between nucleos(t)ide analogue therapy for hepatitis B and Sjögren’s syndrome: 15‐year analysis of the national database of Taiwan. Journal of Viral Hepatitis 2021; 28(5): 809 doi: 10.1111/jvh.13481
|
6 |
Joan Martínez-Campreciós, Mar Riveiro-Barciela, Raquel Muñoz-Gómez, María-Carlota Londoño, Mercé Roget, Miguel Ángel Serra, Desamparados Escudero-García, Laura Purchades, Manuel Rodríguez, Juan E. Losa-García, María L. Gutiérrez, Isabel Carmona, Javier García-Samaniego, Luís Morano, Ignacio Martín-Granizo, Marta Montero-Alonso, Martín Prieto, Manuel Delgado, Natalia Ramos, María A. Azancot, Francisco Rodríguez-Frías, Maria Buti. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy. Gastroenterología y Hepatología (English Edition) 2023; 46(8): 594 doi: 10.1016/j.gastre.2022.12.004
|
7 |
Patricio E. Ray, Asha Moudgil, Aditi Sinha. Pediatric Nephrology. 2021; : 1 doi: 10.1007/978-3-642-27843-3_101-1
|
8 |
Fabrizio Fabrizi, Federica Tripodi, Roberta Cerutti, Luca Nardelli, Carlo M. Alfieri, Maria F. Donato, Giuseppe Castellano. Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease. Viruses 2022; 14(11): 2570 doi: 10.3390/v14112570
|
9 |
Renin Chang, Ming Li Chen, Cheng-Li Lin, Yao-Min Hung, James Cheng-Chung Wei. Association of Infection With Human Papillomavirus and Development of End-Stage Kidney Disease in Taiwan. JAMA Network Open 2020; 3(10): e2022107 doi: 10.1001/jamanetworkopen.2020.22107
|
10 |
Pei-Yuan Su, Yang-Yuan Chen, Jun-Hung Lai, Hung-Ming Chen, Chih-Ta Yao, I-Ling Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Shun-Sheng Wu, Fu-Yuan Siao, Hsu-Heng Yen. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. Journal of Clinical Medicine 2021; 10(22): 5236 doi: 10.3390/jcm10225236
|
11 |
Hsu-Heng Yen, Pei-Yuan Su, I-Ling Liu, Ya-Yuei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Chia-Wei Yang, Yang-Yuan Chen. Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients. PeerJ 2021; 9: e10944 doi: 10.7717/peerj.10944
|
12 |
Giovana Rossato, Cristiane Valle Tovo, Paulo Roberto Lerias de Almeida. Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes. The Brazilian Journal of Infectious Diseases 2020; 24(1): 25 doi: 10.1016/j.bjid.2019.10.011
|
13 |
Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit, Ezequiel Ridruejo. Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología 2021; 41(5): 578 doi: 10.1016/j.nefro.2021.01.008
|
14 |
Hsu-Heng Yen, Pei-Yuan Su, Ya-Huei Zeng, I-Ling Liu, Siou-Ping Huang, Yu-Chun Hsu, Yang-Yuan Chen, Chia-Wei Yang, Shun-Sheng Wu, Kun-Ching Chou, Tatsuo Kanda. Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLOS ONE 2020; 15(8): e0237582 doi: 10.1371/journal.pone.0237582
|